Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 3/20 | 0.42 |
| ▸ | DAGLB | Q8NCG7 | 2/20 | 0.37 |
| ▸ | DAGLA | Q9Y4D2 | 2/20 | 0.37 |
| ▸ | TBXAS1 | P24557 | 7/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | PTAFR | P25105 | 4/20 | 0.36 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5773324 | 0.93 | CYP3A4 (0.41) | NAMPTTBXAS1CYP3A4PTAFRGAA | |
| SCHEMBL5773874 | 0.92 | MAPT (0.42) | NAMPTDAGLBDAGLATBXAS1CYP3A4 | |
| SCHEMBL5773577 | 0.89 | NAMPT (0.35) | NAMPTDAGLBDAGLAGRM2 | |
| SCHEMBL5774478 | 0.84 | HIF1A (0.42) | NAMPTTBXAS1CYP3A4 | |
| SCHEMBL5771831 | 0.83 | HDAC8 (0.34) | NAMPTCYP3A4 | |
| SCHEMBL5777440 | 0.82 | HDAC8 (0.35) | CYP3A4 | |
| SCHEMBL5775722 | 0.82 | GSK3B (0.41) | NAMPTDAGLBDAGLA | |
| SCHEMBL5777281 | 0.81 | HDAC8 (0.34) | CYP3A4 | |
| SCHEMBL5774087 | 0.80 | CNR1 (0.36) | — | |
| SCHEMBL5774849 | 0.80 | HDAC4 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060084690-A1 | Isoxazole derivatives | MOMOSE YU | 2006-04-20 | — | — | US | disclosed |
| US-7022725-B2 | Isoxazole derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-04-04 | — | — | US | disclosed |
| US-20040048908-A1 | Isoxazole derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-03-11 | — | — | US | disclosed |
| EP-1340749-A1 | ISOXAZOLE DERIVATIVES | Takeda Chemical Industries, Ltd. (JP) | 2003-09-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060084690-A1 | Isoxazole derivatives | INSR, GPR119, INSRR | NAMPT 2451/4885DAGLB 3027/4885DAGLA 2703/4885 |
| US-20040048908-A1 | Isoxazole derivatives | GPR119, INSR, IRS1 | NAMPT 2378/4885DAGLB 2102/4885DAGLA 1568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.